Aman, just wanted to reconfirm your view on India here. So, you mentioned, you think 7% to 8% growth that IQVIA is showing looks credible and you mentioned that's the kind of growth you expect going forward. Actually, this appears to be a slowdown because historically we have seen growth rate somewhere closer to 10%. Now, this seems to be structural in nature given we see many companies launching trade generic, we are seeing the Jan Aushadhi volumes picking up and some pharmacies launching generic medicines and pushing private labels, don't you think these are structural changes which are happening in the industry which is dragging down the overall growth?
My second question is on the U.S. market . We have seen sequential drop in sales. So, this rationalization was something specific for this quarter and also you mentioned about on co launch. What kind of cost would have hit our P&L because of this facility commissioning , if you can give some numbers around that?